Comparative study for the effect of magnesium sulfate vs. diclofenac sodium in the prevention of postoperative pancreatitis after ERCP

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900020780

Enrollment

Unknown

Registered

2019-01-19

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-ERCP pancreatitis

Interventions

1: preoperative rectal NSAIDs

2:spraying with high-concentration magnesium sulfate intraoperatively

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All patients aged 18 to 80 years old who received ERCP

Exclusion criteria

Exclusion criteria: 1. Previous ERCP operation was performed with papillotomy or balloon dilatation, duodenal papilla accompanied by biliary fistula; 2. Contraindications to ERCP: upper gastrointestinal obstruction, cardiopulmonary insufficiency, cerebral infarction and cerebral hemorrhage; 3. Active pancreatitis; 4. Grade II or above conduction block 5. Contraindications for NSAIDs: active gastrointestinal bleeding or renal insufficiency within 4 weeks, serum creatinine >120 u/l; 6. Taking NSAIDs continuously; 7. Taking magnesium within 2 weeks; 8. Abnormal coagulation function or anticoagulation therapy; 9. Breastfeeding and pregnant women.

Design outcomes

Primary

Measure	Time frame
amylase;	—

Countries

China

Contacts

Public ContactChen Youxiang

The First Affiliated Hospital of Nanchang University

chenyx102@126.com+86 13879169980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026